1.66 0.18 (12.16%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 1.98 | 1-year : | 2.31 |
Resists | First : | 1.7 | Second : | 1.98 |
Pivot price | 1.28 | |||
Supports | First : | 1.36 | Second : | 1.15 |
MAs | MA(5) : | 1.42 | MA(20) : | 1.31 |
MA(100) : | 1.55 | MA(250) : | 2.23 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 90.1 | D(3) : | 73.3 |
RSI | RSI(14): 67.1 | |||
52-week | High : | 4.32 | Low : | 0.87 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ THTX ] has closed Bollinger Bands are 6.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 1.66 - 1.67 | 1.67 - 1.67 |
Low: | 1.44 - 1.44 | 1.44 - 1.45 |
Close: | 1.65 - 1.66 | 1.66 - 1.67 |
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Wed, 27 Mar 2024
What is the Market's View on Theratechnologies Inc (THTX) Stock's Price and Volume Trends Wednesday? - InvestorsObserver
Fri, 22 Mar 2024
Theratechnologies shifts focus, phases down preclinical research By Investing.com - Investing.com
Thu, 21 Mar 2024
Theratechnologies Appoints Jordan Zwick to its Board of Directors - Yahoo Finance
Thu, 29 Feb 2024
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau - GlobeNewswire
Wed, 21 Feb 2024
Theratechnologies Inc. (THTX) Q4 2023 Earnings Call Transcript - Seeking Alpha
Wed, 07 Feb 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Theratechnologies Inc ... - PR Newswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
Shares Out | 46 (M) |
Shares Float | 34 (M) |
Held by Insiders | 6.2 (%) |
Held by Institutions | 50.8 (%) |
Shares Short | 27 (K) |
Shares Short P.Month | 21 (K) |
EPS | -0.92 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -0.45 |
Profit Margin | -29.3 % |
Operating Margin | 16.6 % |
Return on Assets (ttm) | -6.4 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 9.5 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 1.77 |
EBITDA (p.s.) | -0.13 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -6 (M) |
Levered Free Cash Flow | -1 (M) |
PE Ratio | -1.83 |
PEG Ratio | 0 |
Price to Book value | -3.69 |
Price to Sales | 0.93 |
Price to Cash Flow | -13.44 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |